Shots: Novo Nordisk plans to initiate a pivotal P-llla program to evaluate the efficacy and safety of Semaglutide (oral, 14mg, qd) vs PBO in 3,700 patients with AD with the anticipated initiation in H1’21 The decision follows the evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular […]Read More
Tags : Alzheimer Disease
Shots: The submission is based on P-lll EMERGE and ENGAGE study assessing aducanumab vs PBO in patients with AD. The studies evaluate the efficacy of monthly doses of aducanumab in reducing cognitive and functional impairment The secondary objectives of the study were to assess the effect of monthly doses of aducanumab on the clinical decline […]Read More
Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns PostEra […]Read More
Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial The focus of the agreement is to develop AC Immune’s […]Read More
Shots: The data included results from the ongoing long-term extension (LTE) P-1b study of aducanumab for the treatment of Alzheimer Disease The results for each dose are same as interimanalyses showing decreasing level of amyloid plaque when measured with PET, in dose and time-dependent manner in titration and FD cohorts The study (N=196) patients receives […]Read More